World’s first fast-acting anti-rabies drug Rabies Human Monoclonal Antibody (RMAb) will be launched in India.
The drug has been developed by Pune-based Serum Institute of India (SII) and US-based MassBiologics of the University of Massachusetts Medical School.
About RMAb
RMAb drug is a human IgG1 monoclonal antibody that instantly deactivates rabies virus by specifically binding to a conformational epitope of G glycoprotein of the virus.
It is 25% cheaper compared to the existing expensive human rabies immunoglobulin (hRIG) treatment.
It has advantage of automatically precluding the chances of transmitting blood-borne infections that are present in rabies immunoglobulin vaccines.
The drug has been manufactured using recombinant DNA technology that includes inserting DNA encoding antigen (such as a bacterial surface protein) to the microbial DNA of cells in the body to stimulate immune response.
During various phases of human clinical trials of RMAb spanning 9 years in India and abroad, the drug was found to be safe and effective.
Current Affairs 23rd February, 2016 Current Affairs Question and Answers Round Up January. Current Affairs Round up January, 2016.
Join The Discussion